5/31/2018: On May 29, 2018 I was issued US patent 9,982,963 B2
A firearm having tactile biofeedback reference feature.
It is based upon the same human response to sensation in the skin that was present in the grooved grip and the real feel gloves. It allows the person to shoot more accurately.
5/24/2018: Just learned that on June 5, 2018, U.S. Patent No. 9,987,296 will be published.
It is a continuation of a prior more general patent for intra articular injection to treat arthritis. This patent expanded the use of the common plant dye, Cyanidin-3-glucoside to include dextrose and addition of insulin or other growth hormones as well as slow release biodegradable vehicle.
Allowed Claims
1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject by an intra-articular injection, a composition comprising cyanidin-3-glucoside (C3G), glucose and a pharmaceutically acceptable carrier, wherein the concentration of glucose is about 5%, and wherein the C3G is administered at a dose of 0.002 mg to 100 mg per joint that is effective to elicit the inhibition of IL-1 induced GAG release in the arthritic joint of the subject.
2-3. (Cancelled)
4. The method according to claim 1, wherein the composition increases expression of IGF-1 in the arthritic joint.
5. The method according to claim 4, wherein the composition is provided in a biodegradable microsphere.
6. The method according to claim 5, wherein the biodegradable microsphere comprises a slow release bioabsorbable material.
7. The method according to claim 6, wherein the bioadsorbable material is 50/50 D, L lactide/glycolide or 85/15 D, L lactide/glycolide.
8. (Cancelled)
9. The method according to claim 1, wherein the composition has a chondroprotective and/or chondronutritive effect in the joint of a subject.
10. (Cancelled)
11. The method of claim 1, wherein the composition treats damaged cartilage in the arthritic joint.
12-15. (Cancelled)
16. The method of claim 1, wherein the joint is a synovial joint.
17. The method of claim 11, wherein the injection comprises the formation of anthocyanin metabolites in the synovial fluid.
18. The method according to claim 1, wherein the dose of 0.002 mg to 100 mg per joint of C3G is provided at a concentration not exceeding about 100 µM.
19. The method according to claim 1, wherein the composition is administered with IGF-1, insulin, or a mixture thereof.
20. A method for treating damaged cartilage in an arthritic joint in a subject, comprising administering into the arthritic joint of the subject, by an intra-articular injection, a composition that is a solution comprising an anthocyanin, glucose and a pharmaceutically acceptable carrier, wherein the concentration of the glucose is about 0.5% to about 10%;
wherein the anthocyanin is cyanidin-3-glucoside (C3G), and wherein the C3G is administered at a dose of 0.002 mg to 100 mg per joint.
21. The method according to claim 20, wherein the composition increases production of insulin-like growth factor-1 (IGF-1) in the joint.
22. The method according to claim 20, wherein the glucose is administered at about 5%.
23. The method according to claim 20, wherein the glucose is administered at about 10%.
5/24/2018: The background is important in appreciating the value of this patent.
Before antibiotics, bacteria were free floating in the body as individual bacteria.
There response to anti biotics was to mutate and or form colonies covered with a protective coating of a biofilm that the antibiotic could not penetrate. A total joint implant becomes infected when the first step the bacteria do is to produce a biofilm on the implant and from there, they grow the covered colony.
This US patent is important in that the solution applied to a total joint implant blocks the attachment of a biofilm and therefor the bacteria remain vulnerable to the protocatechuic acid (PCA) which destroys the biofilm and the bacteria.
This patent also provides a means to coat bandages in the manufacturing process. The PCA dries. When applied to a moist wound, the PCA is activated and kills the bacteria and causes would healing acceleration.
Allowed Claims
1. A method of reducing growth or development of a biofilm on a surface, comprising: contacting the surface with a composition comprising about 10% to about 50% of an anthocyanin metabolite or an anthocyanidin metabolite selected from protocatechuic acid and 2,4,6-trihydroxybenzaldehyde and mixtures and combinations thereof, wherein the contacting step reduces an initial attachment of a biofilm or a biofilm forming microorganism to the surface, thereby reducing the growth or development of the biofilm on the surface.
2. The method of claim 1, wherein the biofilm forming microorganism is selected from a Pseudomonas aeruginosa and a Methicillin-resistant Staphylococcus aureus.
3. The method of claim 1, wherein the composition is selected from a liquid, a sanitizer, a disinfectant, a swab, a salve, soap, foam, cream, solution, gel, spray, powder, crystals, antibacterial treatments, wipes, a lotion and combinations thereof.
4. The method of claim 1, wherein the surface is selected from a solid surface, a smooth surface, a porous or semi-porous surface, and a cloth-like surface.
5. The method of claim 1, wherein the surface is on an implant, a bandage, a catheter, a dressing, a heart or vascular grafts, or a wound.
6. The method of claim 1, wherein the surface is a ceramic surface.
7. The method of claim 1, wherein the contacting step is selected from wiping the surface, spraying the surface, soaking the surface, imbedding crystals of the anthocyanin metabolite or an anthocyanidin metabolite on or in the surface, or applying a bandage or wound dressing impregnated with the composition to the surface.
8. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is present in an amount of from about 10% to about 40% by weight of the composition.
9. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is present in an amount of from about 20% to about 30% by weight of the composition.
10. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is protocatechuic acid.
11. The method of claim 1, wherein the surface is contacted with the composition for up to two years.
12. The method of claim 3, wherein the composition comprises protocatechuic acid or 2,4,6–trihydroxybenzaldehyde or a mixture or combination thereof dissolved in a solution.
13. The method of claim 12, wherein the solution further comprises a carrier.
14. The method of claim 13, wherein the carrier is selected from water, isopropyl alcohol, and ethyl alcohol.
15. The method of claim 14, wherein the isopropyl alcohol is present at a concentration of about 70% to about 91%.
16. The method of claim 14, wherein the solution comprises 10% to 30% protocatechuic acid dissolved in about 70% isopropyl alcohol.
4/11/2018: The US Patent office issued # 9,925,152 B2 on March 27, 2018. This was a continuation of the parent patent 9,498,413 which claimed protocatechuic acid as a broad spectrum antibiotic and a wound healing accelerator.
The additional claims indicated the collagen formation properties and potential to reduce scar formation. The clinical application may accompany cosmetic exfoliation and surgical dermabrasion yielding a form of skin wrinkle treatment.
See these granted claims.
10. The method of claim 1 wherein the treating of the wound is a cosmetic method of treating skin to enhance skin healing, wherein the composition is administered topically, orally or by intradermal or subcutaneous injection to a skin tissue, wherein the composition promotes an effect selected from the group consisting of reducing inflammation, optimizing growth hormone production, and increasing collagen stimulation.
11. The method according to claim 1, wherein said administration further results in reduced scar formation.
2/16/2018: Alex Gorsky, the CEO of Johnson & Johnson recently made the following statements concerning where healthcare innovation is headed.
Here is what I think about each of his factors listed in bolding.
There must be a sense of urgency. This is rarely seen in health care because they are slow to change their culture or way of doing business. Why is there no change? The have been successful in doing what they always have done.
This requires us to actually re-imagine Johnson & Johnson as a 132-year-old startup. The cultural background and personalities of those who came up through this system does not allow them to imagine what it takes to be a start up; personal risk, handling failure, more time than anticipated, and the idea of trying again.
One that embraces and acts on the best ideas. This is unlikely to happen since “corporate’s” idea of the best ideas are ones that produce profit in the next quarter, not five years from now when they will be retired or at another company.
One that is nimble and fast. This is unlikely as the junior officers are not going to risk loosing their job by proposing an idea or plan that requires a fast and nimble approach to new products. They know that no one got to the top of “corporate” doing it this way.
One that leverages technology to drive life-changing and life-saving innovation. The risk adverse culture will never leverage as this word contains risk. Let me give you an example. There is a US patented way to coat total joint implants at the time of surgery to prevent attachment of biofilm bacterial colonies. The major orthopedic industry will not take this on because of the estimate of 10 years and 50-150 million dollars to get through the FDA. They cannot even entertain a known less expensive way in time and money to get there.
One that focuses on being competitive always. Being competitive means you are the fittest and fastest with the most mental toughness. High profits inherent in the major medical companies never have required these characteristics and will not, because it has not been necessary to date for success.
One that embraces transformative products. The corporate mentality of the “Big Pharma” has ignored the nutraceutical industry which incidentally is growing very fast.,
One that has quality services. This factor does exist with present managements, marketing, sales and distribution.
One that has transparent pricing. This is not likely as the R&D and cost of doing business is so high, it requires new blockbuster drugs for cancer to sell for up to $100,000 per patient treatment; yes $100,000. This is not you new aspirin.
One that has all the factors with the consumer top-of-mind. If this was so it would not have been almost 30 years since introduction of a new antibiotic. Why is this? The cost to develop plus regulations would not allow the same profit margin as cancer or arthritis.
Summary Insights: For safety, medical companies usually do acquisitions, not innovations. After all they are in the business of making money.
2/9/2018: The Real Feel Glove initiative was launched at the PGA show in Orlando. Web site is up at www.RealFeelGloves.com. The interesting aspect is the suggestions to so many performance enhancing applications; golf, basketball, football, sport shooting as in Olympics, fly fishing and even musical instruments.
Presently doing testing on PGA tour for supporting evidence. US patent has been granted.
1/7/2018: You may not be the first to make a discovery. I loved this short video’s teaching moment.
https://www.facebook.com/CrazyNews24/videos/1015187725279202/
Design: Solutions by K8